Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12983464 | 0.91 | PTGS1 (0.51) | PTGS2PTGS1PDPK1CYP1A2CYP3A4 | |
| SCHEMBL287214 | 0.86 | PTGS2 (0.51) | PTGS2PTGS1TRPV1 | |
| SCHEMBL31364584 | 0.86 | PTGS2 (0.61) | PTGS2PTGS1PDPK1CYP1A2CYP3A4 | |
| SCHEMBL287490 | 0.86 | TRPV1 (0.51) | PTGS2PTGS1TRPV1 | |
| Hydrochloric Acid SCHEMBL12983419 | 0.85 | PTGS2 (0.50) | PTGS2PTGS1TRPV1 | |
| SCHEMBL31364592 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1PDPK1CYP1A2CYP3A4 | |
| SCHEMBL31364577 | 0.85 | PTGS2 (0.60) | PTGS2PTGS1PDPK1CYP1A2CYP3A4 | |
| SCHEMBL287528 | 0.85 | MAPK14 (0.53) | PTGS2PTGS1TRPV1 | |
| SCHEMBL287402 | 0.84 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL13172610 | 0.84 | TRPV1 (0.46) | PTGS2PTGS1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427435-B1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2017-06-14 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140142143-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-8592471-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| EP-2427435-A1 | SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| WO-2010127856-A1 | SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331381-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | PTGS2 1571/4885PTGS1 1768/4885PDPK1 2118/4885 |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | PTGS2 1336/4885PTGS1 1476/4885PDPK1 1754/4885 |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | PTGS2 1336/4885PTGS1 1476/4885PDPK1 1754/4885 |
| US-20140142143-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV2 | PTGS2 1571/4885PTGS1 1768/4885PDPK1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.